维持平衡:急性缺血性卒中非药物细胞保护治疗新进展
再灌注治疗是急性缺血性卒中(AIS)的标准治疗,但约半数患者即使成功再通仍未恢复功能独立。本文综述非药物细胞保护策略,针对缺血期能量供需、再灌注期低灌注与高灌注、亚急性及慢性期细胞毒性与促修复炎症三对失衡状态,结合近期大规模临床试验结果,探讨其机制与临床应用前景。
要点
- 再灌注后约半数AIS患者未获功能独立,可能与再灌注前后可避免的失衡状态有关。
- 非药物细胞保护为多靶点治疗,针对能量供需、灌注高低及炎症类型三对失衡。
- 近期大规模临床试验为非药物脑细胞保护在AIS中的获益提供了新证据。
核心结论
- 非药物细胞保护治疗为多靶点策略,针对AIS三对失衡状态提供新的获益证据,未来临床试验可进一步优化以推动临床转化。
研究设计与样本
- topical review,讨论非药物策略针对AIS三对失衡状态(缺血期能量供需、再灌注期低灌注与高灌注、亚急性及慢性期细胞毒性与促修复炎症)的机制与近期大规模临床试验结果。
主要发现
- 再灌注治疗虽为标准治疗,但约半数患者即使成功再通仍未恢复功能独立,可能与再灌注前后可避免的失衡状态有关。
- 经典药物方法仅针对单一失衡,不足以应对AIS的多重病理生理过程。
- 非药物疗法通常具有多靶点作用,近期大规模临床试验为其在AIS中的获益提供了新证据。
临床怎么用
- 临床应关注AIS再灌注前后能量供需、灌注状态及炎症类型的失衡,考虑多靶点非药物细胞保护策略的潜在获益。
局限性
- 本文为 topical review,未报告原始研究数据,非药物细胞保护策略的临床转化仍需未来试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
引用
- Xu Y, Hu W, Chen X, et al. Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke. Stroke. 2025. PMID: 40836910. doi:10.1161/STROKEAHA.125.051589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。